Renovacare, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 13, 2020 at 09:35 am EST
Share
RenovaCare, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 2.842 million compared to USD 1.200 million a year ago. Net loss was USD 2.817 million compared to USD 1.116 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.01 a year ago. For the nine months, operating loss was USD 7.115 million compared to USD 2.448 million a year ago. Net loss was USD 7.004 million compared to USD 2.182 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.03 a year ago.
RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâs own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâs CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâs own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâs novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.
RENOVACARE, INC. 
